Moracin M is a phosphodiesterase 4 (PDE4) inhibitor (PDE4D2: IC50 = 2.9μM; PDE4B2: IC50 = 4.5μM; PDE5A1: IC50 > 40μM; PDE9A2: IC50 > 100μM) [1]. Moracin M inhibits inflammatory signaling pathways such as NF-κB and MAPK, reducing the production of pro-inflammatory cytokines (such as TNF-α, IL-6, and NO) [2-3]. Moracin M is often used in inflammation research [4].
In human umbilical vein endothelial cells (HUVECs), Moracin M (6.25-25µg/mL;24h) enhances HUVEC tube formation in a dose-dependent manner [5]. In C2C12 cells, Moracin M (25 μM; 48 h) treatment significantly increased myoblast proliferation [6].
In acute lung injury mice model, Moracin M (20mg/kg, 60mg/kg; ig; single administration) inhibits airway inflammation [7]. In LPS-induced mouse airway inflammation model, Moracin M (30mg/kg; po; single administration) effectively reduces airway inflammation in vivo [8].
References:
[1]. Chen S K, Zhao P, Shao Y X, et al. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor[J]. Bioorganic & medicinal chemistry letters, 2012, 22(9): 3261-3264.
[2]. Yao X, Wu D, Dong N, et al. Moracin C, a phenolic compound isolated from Artocarpus heterophyllus, suppresses lipopolysaccharide-activated inflammatory responses in murine raw264. 7 macrophages[J]. International Journal of Molecular Sciences, 2016, 17(8): 1199.
[3]. Chen L, Wu D, Wang S, et al. Moracin M derivative targeting PDE4 for the treatment of psoriasis[J]. Acta Materia Medica, 2025, 4(2): 293-301.
[4]. Guo F, Zou Y, Zheng Y. Moracin M inhibits lipopolysaccharide-induced inflammatory responses in nucleus pulposus cells via regulating PI3K/Akt/mTOR phosphorylation[J]. International immunopharmacology, 2018, 58: 80-86.
[5]. Chang B Y, Hwang Y, Kim I, et al. The Role of Moracin M in Promoting Hair Growth: Insights into Mechanisms of WNT/β-Catenin Pathway Activation and Angiogenesis Enhancement in Human Dermal Papilla Cells[J]. 2024.
[6]. Kwak H J, Kim J, Kim S Y, et al. Moracin E and M isolated from Morus alba Linné induced the skeletal muscle cell proliferation via PI3K-Akt-mTOR signaling pathway[J]. Scientific reports, 2023, 13(1): 20570.
[7]. Lee J H, Ko H J, Woo E R, et al. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo[J]. European journal of pharmacology, 2016, 783: 64-72.
[8]. Lee J, Mandava S, Ahn S H, et al. Potential moracin M prodrugs strongly attenuate airway inflammation in vivo[J]. Biomolecules & Therapeutics, 2020, 28(4): 344.
Moracin M是一种磷酸二酯酶4（PDE4）抑制剂（PDE4D2：IC50 = 2.9μM；PDE4B2：IC50 = 4.5μM；PDE5A1：IC50 > 40μM；PDE9A2：IC50 > 100μM） [1]。Moracin M抑制NF-κB和MAPK等炎症信号通路，从而减少促炎细胞因子（如TNF-α、IL-6和NO）的产生 [2-3]。Moracin M常用于炎症研究 [4]。
在人脐静脉内皮细胞（HUVEC）中，Moracin M（6.25-25µg/mL；24h）以剂量依赖性方式增强HUVEC管腔形成 [5]。在C2C12细胞中，Moracin M（25μM；48h）处理显著促进成肌细胞增殖 [6]。
在急性肺损伤小鼠模型中，Moracin M（20mg/kg，60mg/kg；ig；单次给药）可抑制气道炎症 [7]。在LPS诱发的小鼠气道炎症模型中，Moracin M（30mg/kg；po；单次给药）可有效减轻体内气道炎症 [8]。